H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on IVERIC bio (NASDAQ:ISEE) Inc on Wednesday, setting a price target of $26, which is approximately 43.65% above the present share price of $18.1.
Caufield expects IVERIC bio Inc to post earnings per share (EPS) of -$0.32 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in IVERIC bio, with an average price target of $22.4.
The analysts price targets range from a high of $26 to a low of $18.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$30.21 million. The company's market cap is $2.07 billion.
According to TipRanks.com, H.C. Wainwright analyst Matthew Caufield is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 82.9% and a 100.00% success rate.
IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.